iBio Inc, IBIO Securities Lawsuit
Lucy Campbell, 16 December 2014
Los Angeles, CA: A securities class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of investors who purchased iBio, Inc. (“iBio” or the “Company”) (NYSE MKT:IBIO) securities between October 13, 2014 and October 23, 2014.
The Complaint alleges that during the Class Period, the Company issued materially false and misleading statements to investors by wrongfully suggesting that the Company’s Launch platform patents and related proprietary technology would be licensed by the makers of the experimental Ebola drug, ZMapp. The Complaint alleges that when the true facts were revealed, the price of the Company’s stock fell significantly, damaging investors.
